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efficacy and visual outcomes of a large series of patients with 
choroidal melanoma (CM) treated with RuBT, and compare 
the results to those of the preceding protocol in which RuBT 
was combined with transpupillary thermotherapy (Ru/TTT). 
 
Material and Methods: Outcomes of 449 consecutive CM 
patients with tumour prominence <8 mm and basal diameter 
<16 mm treated with RuBT from 2004 to 2011 were analysed. 
253 (56.3%) were treated according to the current RuBT 
protocol (from 2008 onwards) with 130 Gy specified at the 
tumour apex and minimum and maximum doses to the scleral 
surface of 300 Gy and 1000 Gy, respectively. 196 (43.6%) 
were treated using the preceding Ru/TTT protocol with 
either 400 or 600 Gy to the scleral surface followed by TTT, 
or 600-800 Gy without TTT for peripheral tumour location. 
The brachytherapy dose was standardized to a dose rate of 
100 Gy per 24 h using a correction factor (2-10% dose 
correction). Local failure was defined as residual prominence 
with signs of activity on fluorescence angiography, or 
regrowth after complete remission. 
 
Results: Median follow-up was 40.1 months; 25.9 months for 
RuBT and 67.5 months for Ru/TTT; hence 3-year results were 
analysed. Patients treated with RuBT had smaller and less 
centrally located tumours and better median visual acuity 
(VA). VA deteriorated more rapidly in Ru/TTT patients; at 1 
year the loss of vision relative to the VA before treatment 
was -0.1 for RuBT patients vs -0.25 for Ru/TTT, while at 3 
years the relative VA decline was similar (-0.30 vs. -0.28). 
Local failure was detected within 3 years in 4.3% of RuBT 
patients compared to 11.2% of Ru/TTT patients, for 3-year 
cumulative incidence rates of 6.4% vs 11.2% (p=0.09). 
Treatment for local failure consisted of repeated RuBT; TTT; 
or enucleation. Enucleation was performed in 2.4% of RuBT 
patients vs. 10.2% of Ru/TTT; of these, 1.6% vs 6.1% were 
done for recurrence and 0.8 vs 4.1% for complications. Three-
year cumulative incidence of distant metastases was 4.8% vs 
6.6% for RuBT vs Ru/TTT (p=0.37), and of death 0.5 vs 3.7%. 
In univariate analyses, most important risk factors for local 
recurrence and metastases were tumour prominence, tumour 
diameter and stage, while in multivariate analysis only 
diameter remained significant for local recurrence. In view of 
the short follow-up of RuBT, updated results will be 
presented. 
 
Conclusion: Both protocols for eye-conserving treatment of 
patients with choroidal melanoma provided excellent rates of 
local tumour control and eye preservation, with the RuBT 
protocol confirmed to be best standard of care with 97% eye 
preservation and significantly longer preservation of visual 
acuity. 
 
Poster: Clinical track: Sarcoma  
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Purpose or Objective: The standard primary treatment for 
soft tissue sarcoma (STS) is radical surgical resection, 
preceded or followed by radiotherapy. The purpose of this 
retrospective study was to assess the efficacy and safety of 
perioperative brachytherapy (BT) plus postoperative external 
beam radiation therapy (EBRT) +/- chemotherapy (CT). 
 
Material and Methods: The primary aim of the study was 
evaluating local control (LC) and overall survival (OS) in a 
large patients population of treated with combined modality 
therapy. Secondary objectives were to identify prognostic 
factors for local recurrence (LR). BT was delivered with 
Pulsed Dose Rate. Total dose was 20 Gy (0.80 Gy/pulse). 
EBRT was delivered with 3D-technique by using multiple 
beams technique. The prescribed dose was 46 Gy 
(2Gy/fraction). Neoadjuvant and adjuvant chemotherapy was 
prescribed to patients with potentially chemo-sensitive 
histological subtypes. Univariate analysis was performed with 
the log-rank test and multivariate analysis with Cox’s 
proportional hazard model.  
 
Results: From 2000 to 2011, 107 patients (median age 54 
years; range 13-85) with high grade primary or recurrent STS 
were treated with surgery, perioperative BT and adjuvant 
EBRT +/- CT. Five year LC and OS were 82.2% and 87.8%, 
respectively. A higher LC was recorded in patients treated for 
primary tumor, lower limbs, and negative margins STS. 
 
Conclusion: The combination of BT and EBRT was able to 
achieve high LC and OS rates. A particular risk factor 
recorded was the disease site. These results warrant further 
prospective studies to define the role of BT boost in adjuvant 
therapy of resected STS.  
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Purpose or Objective: Primary cardiac and great vessel 
sarcomas are a challenging group of cancers with poor 
prognosis. No consensus management guidelines exist and 
definitive treatment favours surgery, reserving adjuvant 
radiotherapy (RT)/chemotherapy (CT) for high-risk patients. 
 
Material and Methods: Retrospective analysis of patients 
identified from a prospectively collected database Sarcoma 
Unit, 2000-2014. 
 
Results: 33 patients(19 males) were identified with either 
primary cardiac(73%) or great vessel sarcomas; median age of 
46.9 (range 13-83). Presenting symptoms included 
dyspnoea(55%), pain(21%), cough/haemoptysis(11%), heart 
failure(24%), emboli(18%) or pulmonary HTN(12%). Diagnosis 
was on biopsy(42%) or following resection(58%). Atrial 
tumours accounted for 58% of cases. Surgery was performed 
in 66%, with R0(12%),R1(24%) ,R2(24%), or unknown (6%) 
margins. High grade tumours were seen in 17(52%) cases. 
Commonest histological subtypes were angiosarcoma (32%), 
and spindle cell (17%). Localised disease was observed in 18 
(55%) cases. Median follow-up was 379 days. 
Group A, Radiotherapy: 15 patients received RT (6 males), 10 
had operable tumours. 8 patients also received CT. Median 
time to first treatment was 57.9 days. Patients received 60 
Gy/30#(n=4), 59.4 Gy/33#(n=3), 58 Gy/30#(n=1), 50.4 
Gy/28#(n=3), 45 Gy/25#(n=1), 35 Gy/15#(n=1), or 20 
Gy/5#(n=1). 85% reported toxicity (oesophagitis, cough or 
fatigue). 8 (53%) patients developed a local recurrence (LR) 
and 13 patients developed metastatic disease (DM). 2 were 
long term survivors. Median time to DM for right sided lesions 
was 116 days, left sided, 1226 days. Overall survival was 2.1 
years (R side) and 3.4 years (L side). Median OS was 803 days.  
Goup B, Chemotherapy: 13 patients received CT(10 males), 7 
had operable tumours. Median time to first treatment was 44 
days. Regimens were mainly alkylating/anthracycline/taxane 
based. 3 patients stopped early (toxicity). 10 patients had 
LR(77%) and 10 patients developed DM. 2 were long term 
survivors. Median OS was 296 days. 
Group C, Surgery: 
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5 patients, 1 died 3 days after diagnosis. 4 patients had 
surgery, 3 developed DM and 1 is a long-term survivor. 
Median OS was 68 days. 
 
 
 
Conclusion: These rare sarcomas have variable clinical 
presentations. Surgery is the central component for 
successful treatment but complete resection is not always 
possible. RT may reduce LR (reduced from 77%, group B,to 
53%, group A) and chemotherapy is offered if high risk 
(inoperable, R2 margins, or DM). We still need to define the 
optimum management. 
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Purpose or Objective: To evaluate the impact of a dose 
escalation > 50 Gy in a large series of resected limbs soft 
tissue sarcomas (STS) 
 
Material and Methods: Data were retrospectively analyzed 
from 414 consecutive localized limbs STS patients who 
received irradiation and enlarged surgery at Gustave Roussy 
from 05/1993 to 05/2012. RT dose level were decided in 
multidisciplinary staff and depended upon the quality of 
surgery and margins size. 
 
Results: The median age was 52 years, the median tumor size 
was 89 mm, most patients had proximal locations (72%), and 
G-2-3 tumors (79%). Available histologic analyses after 
surgery retrieved 84% unifocal tumors and free-tumor margins 
>1 mm in 69% of cases. Radiotherapy (RT) was delivered prior 
(13%) or after (87%) surgery. Seven patients (2%) had pre- and 
a postoperative RT boost. Median delivered RT dose was 50 
Gy (36-70 Gy), and 40% received >50Gy. At a median follow-
up of 5.5 years, the 5-year local relapse rates (LRRs) were 
7%, 4%, and 13% in the general population, in patients 
receiving <50Gy and in those who had >50 Gy (p<0.001), 
respectively. Despite this may due to confounding factors, a 
dose >50 Gy (HR: 2.6; p=0.04) remained associated with 
higher LRRs in the multivariate analysis (MVA), as well as 
histological subtypes (HR: 3.7; p=0.002), and surgical 
margins<1mm (HR: 3.2; p=0.008). Grade, age, and tumour 
size were not associated with LRRs in the MVA. 
 
Conclusion: In this retrospective analysis of patients having 
enlarged and surgery and RT dose escalation did not allow 
offsetting local relapse in high-risk patients. This should be 
evaluated in a larger set of patients all having enlarged 
surgery. A Prospective study allowing dose refinement in this 
setting is required. 
 
 
PO-0767  
Does fluid collection have an impact on radiotherapy 
outcomes after excision of soft tissue sarcoma? 
N. Choi
1Seoul National University College of Medicine, Department 
of Radiation Oncology, Seoul, Korea Republic of 
1, J.Y. Kim1, T. Yu1, H.S. Kim2, H.J. Kim1, I.H. Kim1 
2Seoul National University College of Medicine, Department 
of Orthopaedic Surgery, Seoul, Korea Republic of 
 
Purpose or Objective: Fluid collection of lymph or blood may 
accumulate at the site of excision after surgery for soft tissue 
sarcoma, with reported incidence rates from 10-36%. Though 
small fluid collections have a high probability of being 
completely covered within the postoperative radiotherapy 
(PORT) field, large fluid collections may require a more 
extensive expansion of CTVs. This study is an unprecedented 
analysis of fluid collection in relation to radiotherapy 
outcomes after wide excision of soft tissue sarcoma (STS). 
 
Material and Methods: Medical records of 151 patients with 
STS treated with wide excision followed by adjuvant PORT 
between 2004 and 2014 were retrospectively reviewed. Only 
non-recurrent and non-metastatic patients were included. 
After evaluation of CT and MR images taken at the time of 
PORT planning, fluid collection was detected in 46 patients 
(30.5%). Because fluid collection developed more commonly 
in lower extremity (p<0.001) and higher grade tumors 
(p=0.095), only these patients were included in further 
analyses (n=76). Fluid collection was present in 35 (46.1%) 
patients, of which 74.3% and 25.7% had, respectively, either 
complete or partial coverage in planning target volumes 
(PTVs) throughout the entire course of PORT. 
 
Results: After a median follow-up of 41 months, patients 
with and without fluid collection demonstrated local failure 
rates of 14.3% and 9.8%, and 5-year local control (LC) rates of 
83.1% and 86.8%, respectively. The presence of fluid 
collection had no statistical impact on the clinical outcomes 
of PORT. Partial coverage of fluid collection showed a low 5-
year LC rate of 77.8% compared with 85.5% and 86.8% for 
patients that had complete PTV coverage or absence of fluid 
collection, respectively, without statistical significance. Post-
PORT complications developed in 5 (6.6%) patients, of which 
4 had fluid collection. Wound complication developed in 3 
(8.6%) of 35 patients with fluid collection and in 1 (2.4%) of 
41 patients without fluid collection. 
 
Conclusion: Fluid collection demonstrated lower LC rates 
after wide excision and PORT for STS, but with a reasonable 
wound complication rate of 8.6% when compared with rates 
of previous studies ranging from 5-17%. Furthermore, partial 
coverage of fluid collections in PTVs had worse LC rates, thus 
recommending complete coverage. Future evaluation wth a 
larger number of cases will be needed for statistical support 
of our findings. 
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